Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab

There is little evidence regarding the maintenance of long-term clinical remission by adalimumab (ADA) therapy in Crohn’s disease (CD) patients naïve to anti-tumor necrosis factor treatment (naïve CD patients), since most CD patients are treated with ADA after infliximab (IFX) therapy. The long-term...

Full description

Bibliographic Details
Main Authors: Tsutomu Mizoshita, Satoshi Tanida, Keiji Ozeki, Takahito Katano, Takaya Shimura, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh
Format: Article
Language:English
Published: Karger Publishers 2016-06-01
Series:Case Reports in Gastroenterology
Subjects:
Adalimumab
Biologically naïve Crohn’s disease
Serum trough level
Infliximab
Online Access:http://www.karger.com/Article/FullText/445105

Internet

http://www.karger.com/Article/FullText/445105

Similar Items